Anavex is a clinical stage biotech company primarily focused on development of Anavex 2-73, whose most “advanced” indication is for Alzheimer’s, currently underway in its phase IIa trials.
We do not view Anavex as capable of progressing the compounds currently under development into potential candidates for FDA approval. The Company is most likely not even capable of conducting actual research given their employee count (seven), lack of IP (~5 patents listed issued in Greece with very little correlation to the business), lack of R&D spend (about $5 million over the operating history, most to conduct trials), and de minimis PP&E value ($700 in computer equipment). Instead we view Anavex as a scheme well designed to capture financing from investors to payout management (in excess of R&D spend). Anavex is nothing more than a trading sardine, once buyers realize the sardines do not in fact cure cancer, there will be no value.
In this write up I will lay out the evidence that proceeds my confidence in this claim and detail why, within the year, Anavex will again be trading at a near zero equity value on the OTC, or even worse suspended as a result of a current SEC investigation underway.
We think Anavex is a short at these levels because AVXL previously underwent a paid promotion scheme whereby the share price hit $15; since then, investors and sell-side have been irrationally using this number as an anchoring point for valuation. Furthermore, recent articles promoting Anavex online have helped pushed up the share price nearly 60% over the past month, today it is down 30% but it is still worth 0. We do note that other informed investors have come up with the same thesis as ours. We have similarly been following the story for a year now. We only now propose the short given strong upcoming catalysts and timely market movements. Without this setup we would be hesitant to take the other side of large retail buying at a high borrow cost.
The company was founded by Tom Skarpelos, an individual with sparse information online. Looking a little bit more in depth reveals he was the head of IR at Acrongenomics, which is now worthless having had its registration revoked by the SEC
Tom Skarpelos, the founder of Anavex, created the company by conducting a reverse merger through an OTC shell called Thrifty Printing.
In October 2015, the company conducted a 1:4 reverse stock split and was uplisted to the Nasdaq. Around the same, the company underwent a paid promotion scheme (more below).
Management does not have a core competency in the biotech space. The CEO, Christopher Missling, has a background in investment banking and has previously held numerous head of finance positions at other biotech firms. He was recently a partner at Brimberg & Co, an “investment bank” which in May of 2013 was expelled from membership in FINRA after it failed to pay fines levied after the firm “failed to timely respond to FINRA requests for information and documents” . Per his background, the CEO has a well rounded knowledge space into how to raise capital, but not so much into how to create groundbreaking treatments for previously incurable diseases.
The CEO alone makes $2.5m in full pay, more than the company spent on R&D for FY’15.
Christopher is highly promotional, appearing numerous times on micro cap investment interviews such as “stock news now,” to talk up the market size of Alzherimer’s Disease and Anavex.
The CFO, Sandra Boenish, was previously the VP of Finance at Naked Brands, a natorious pump and dump whose once $6bn market cap now sits on the OTC for $10mn. By our accounts Sandra actually resides in Canada; her employment contract with Anavex gives credence to this theory as she is paid in CAD not USD
While the company was executing a 4:1 reverse split, AVXL was actively pumped by paid promoters across the web sending the share price up to nearly $15. Since then, bulls have been using this number as an anchoring point; we view that in the absence of material advancement in the company’s pipeline (as is the case since the pump) that the anchoring to a $15 price point (made possible only by paid web promoters) is irrational behavior.
Others have claimed the paid stock promotion was paid for by Anavex itself. This would seemingly be confirmed by the actual promotional email itself (below, prior to uplisting the ticker was AVXLD). This claim has been vehemently declined by the company, so I will leave it up to the reader’s judgment. I will however supply this quote by Warren Buffet: “Honesty is a very expensive gift. Don’t expect it from cheap people”
The company is plagued by shady characters, among them management, PR firms, financing firms, and corporate partners:
PR: The company has previously used The Primorsis Group, a notorious “press release” company which has been involved in numerous pump and dumps, such as HiEnergy.
Financing: Anavex has accessed funding via converts, warrants, and additional share offerings through Lincoln Park Capital – a firm who has a terrible track record and mostly exists to prey on companies in dire need of financing like Anavex. Anavex engaged LPC in a $50M stock purchase deal in which they “gave Lincoln Park Capital Fund 179,598 shares in exchange for Lincoln Park's agreement to purchase up to $50 million of its shares over the next three years” at Anavex’s discretion.
Partner: In January 2014, the company announced a clinical development partnership with the Roskapm Insititute – a company that was “served with federal criminal subpoenas in 2013 regarding private stock placements, ultimately leading to a 2-year prison sentence"
In response, the CEO said, “Maybe we didn’t know about it at the time, I guess,” said CEO Missling.
Company refuting short sellers:
The CEO responded to allegations that the company paid for stock promotion by saying:
“We are not by any means highly promotional,” adding he would probably have to take legal action against a company “blaming or accusing us.”
“According to the clinicaltrials.gov changes record, in October 2014 Anavex entered changes switching study design to open-label, reducing the number of arms from 8 to 4, and reducing the number of exclusion criteria from 23 to four, with investigator discretion added,”
Kristina Capiak, the VP of Regulatory affairs has actually disputed this, blaming an erroneous change by a “new CRO member.” Oddly she has been very adamant in denying these changes and has posted comments on various forums (such as alzforum.org) claiming the same “new CRO member” as culprit for the changes and has made a similar comment on the clinicaltrials.gov change log.
Clinical Trial data (or lack thereof):
Flaws in current clinical trials and data represented so far:
The main trial data investors is the Anavex 2-73 phase 2a trial readout from January 11, 2016. This trial is inherently flawed as it is an open label. If you give someone a pill and say it is going to help their memory, chances are you will see a slight improvement. Anavex reported that their 2-73 candidate had an 80% probability of achieving a 2 point or higher movement in MMSE score over 5 weeks of treatment. A 5 week period is too short as only in“repeated assessments with 1.5â year intervals [does] change in MMSE of at least 2–4â points indicated a reliable change at the 90% confidence level.”
Furthermore “Small changes in MMSE can be interpreted only with great uncertainty. They have a reasonable probability of being caused by measurement error, regression to the mean or practice.” 
Additionally, we view a major flaw in the phase IIa trial being that n = 32 and the study’s two stage design where all test subjects are evaluated for maximum dosage, but only those who opt in to the program further are tested for cognitive ability.
Dr. Adam Kline, an Alzheimer’s disease research expert who reviewed Anavex 2-73 data said:
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%,"
We do note that a major risk in the short would be investor perception of further clinical trial data which may appear positive (but not statistically valid).
Anavex has appreciated 60% in the past month, today it has dropped over 30% on poor data published. Recent market appreciation was only a result of promotion in widely read retail investor publications like Zacks and Motley Fool. Furthermore, for what it’s worth, it appears bots have been posting positive scripted messages across twitter recently.